Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (19)

2024

  1. Rna-loaded nanoparticles for the treatment of hematological cancers

    Advanced Drug Delivery Reviews, Vol. 214

2018

  1. Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma

    Cancer Letters, Vol. 430, pp. 193-200

2017

  1. Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells

    Cancer Letters, Vol. 388, pp. 262-268

2015

  1. Antitumoral-Lipid-Based nanoparticles: A platform for future application in osteosarcoma therapy

    Current Pharmaceutical Design, Vol. 21, Núm. 42, pp. 6104-6124

  2. Lipid nanoparticles enhance the efficacy of chemotherapy in primary and metastatic human osteosarcoma cells

    Journal of Drug Delivery Science and Technology, Vol. 30, pp. 435-442

2014

  1. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

2013

  1. A simple and robust high-performance liquid chromatography coupled to a diode-array detector method for the analysis of genistein in mouse tissues

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 935, pp. 47-53

2012

  1. Drug Delivery in Tissue Engineering: General Concepts

    Nanostructured Biomaterials for Overcoming Biological Barriers (The Royal Society of Chemistry), pp. 501-526

2011

  1. Lipid Nanoparticles in Biomedicine

    Encyclopedia of Nanoscience and Nanotechnology (American Scientific Publishers), pp. 455 - 478

2010

  1. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts

    Clinical Cancer Research, Vol. 16, Núm. 7, pp. 2046-2054

  2. Lipid raft-targeted therapy in multiple myeloma

    Oncogene, Vol. 29, Núm. 26, pp. 3748-3757

2009

  1. Antitumor alkyl ether lipid edelfosine: Tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice

    Clinical Cancer Research, Vol. 15, Núm. 3, pp. 858-864

2007

  1. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections

    Expert Opinion on Drug Delivery, Vol. 4, Núm. 6, pp. 677-688

  2. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

    Oncologist, Vol. 12, Núm. 9, pp. 1151-1155

2006

  1. Chemical and biological factors in the control of Brucella and brucellosis

    Current Drug Delivery, Vol. 3, Núm. 4, pp. 359-365

2004

  1. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres

    Journal of Controlled Release, Vol. 96, Núm. 3, pp. 437-448

  2. Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: Application to cell uptake studies and characterization of drug delivery systems

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 810, Núm. 1, pp. 85-92

  3. Rapid and simple determination of doxycycline in serum by high-performance liquid chromatography: Application to particulate drug delivery systems

    Journal of Chromatography A, Vol. 1031, Núm. 1-2, pp. 295-301

2003

  1. Development and validation of a liquid chromatographic method for in vitro mupirocin quantification in both skin layers and percutaneous penetration studies

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 796, Núm. 2, pp. 233-241